A bold new initiative is offering a glimmer of hope for our furry friends battling cancer. Dogs with terminal or inoperable cancers now have a chance to leave a lasting legacy, thanks to a groundbreaking project at the University of Queensland.
The project aims to test the power of a drug called Enzistat, an immunomodulatory treatment, in fighting solid tumours caused by naturally occurring cancers in dogs. This includes soft tissue sarcoma, mast cell tumours, and melanoma.
Professor Rachel Allavena, from UQ's School of Veterinary Sciences, encourages owners with dogs facing terminal cancer or inoperable tumours to apply for this trial.
"The treatment involves a simple oral tablet, Enzistat, given twice daily for six weeks, along with regular check-ups, blood tests, and biopsies," Professor Allavena explains.
But here's where it gets controversial... Enzistat is designed to activate the patient's immune system, targeting advanced cancers. Previous trials have shown promising results, with Enzistat achieving tumour regression and extending survival time for palliative patients with late-stage cancers.
The research consists of two trials. The first focuses on terminal patients, aiming to prolong their lives, while the second trial explores whether the drug can shrink large tumours to make surgical removal possible.
To be part of this groundbreaking research, dogs must have a cancer diagnosis from their vet and provide medical records. Researchers will collaborate closely with the dogs' regular vets throughout the trial.
Dogs must also have a predicted survival time of over three months and be able to travel to UQ Gatton for at least three visits over the six-week treatment period.
Solid tumours are a common challenge in canine health, with approximately one in three dogs developing cancer during their lifetime. While canine cancers can be treated with surgery, chemotherapy, and radiotherapy, these options are often limited by cost and availability.
Dr. Jose Granados Soler emphasizes, "Immunotherapeutics is a relatively new field in veterinary medicine, mirroring the approach in human oncology. Our goal is to develop safe, accessible, and affordable immunotherapies that can be administered in general practice."
The team aims to optimize these therapies, either as standalone treatments or in combination with standard care, giving each dog the best fighting chance against cancer.
If your dog meets the eligibility criteria, don't miss this opportunity to be part of this potentially life-changing research. Apply for the trial by contacting uqvets.sa@uq.edu.au.
And this is the part most people miss... By participating, your dog could not only benefit from this innovative treatment but also contribute to a legacy that could change the landscape of canine cancer treatment forever.
So, will you be a part of this groundbreaking journey? We'd love to hear your thoughts and experiences in the comments below!
